26 septiembre 2014
A new strategy for reducing the often serious side effects of an important class of modern anticancer drugs — tyrosine kinase inhibitors has been developed by an international team of researchers. The novel drug is supposed to restrict its activity with high selectivity to the malignant tumor.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/7Egsrl7iGzI/140926112145.htm
